Evidence map›Paper›PMID 17301136›Full record

ArticleJournal of virology2007

Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections.

Shaun K Rodriguez, Abdoulaye Dieng Sarr, Adam MacNeil, Seema Thakore-Meloni, Aissatou Gueye-Ndiaye, Ibrahima Traoré, Mamadou C Dia, Souleymane Mboup, Phyllis J Kanki

Open access · greenAbstract readComparative Study
In one paragraph

Article in Journal of virology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 49 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. The Antibody Response against HIV-1.Cold Spring Harbor perspectives in medicine · 2012
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity.Journal of acquired immune deficiency syndromes (1999) · 2011
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Shaun K RodriguezDepartment of Immunology and Infectious Diseases, Harvard School of Public Health, 651 Huntington Avenue, Boston, MA 02115, USA.
Abdoulaye Dieng Sarr
Adam MacNeil
Seema Thakore-Meloni
Aissatou Gueye-Ndiaye
Ibrahima Traoré
Mamadou C Dia
Souleymane Mboup
Phyllis J Kanki
Harvard University · USCheikh Anta Diop University · SN

Funding

HIV-2 CELLULAR IMMUNITY CROSS-REACTIVE WITH HIV-1R01AI046274 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI KANKI, PHYLLIS J. · 1999 to 2003
$1.2M
NIAID NIH HHS AI46274-04NIAID NIH HHS R01 AI046274
6 · The paper itself

Abstract

Neutralizing antibody responses against heterologous isolates in human immunodeficiency virus type 1 (HIV-1) and HIV-2 infections were compared, and their relationships with established clinical markers of progression were examined. Neutralizing responses against 7 heterologous primary isolates and 1 laboratory strain were compared between 32 untreated HIV-1-infected subjects and 35 untreated HIV-2-infected subjects using a pseudotyped reporter virus assay. The breadth of the neutralizing response, defined as the proportion of panel viruses positively neutralized by patient plasma, was significantly greater among HIV-2-infected subjects than among HIV-1-infected subjects. Notably, for fully one-third of HIV-2 subjects, all viruses were effectively neutralized in our panel. Magnitudes of responses, defined as reciprocal 50% inhibitory concentration (IC(50)) titers for positive reactions, were significantly greater among HIV-1-infected subjects than among HIV-2-infected subjects. When plasma samples from HIV-1 patients were tested for cross-neutralization of HIV-2 and vice versa, we found that these intertype responses are very rare and their prevalences comparable in both HIV-1 and HIV-2 infection. The significantly higher magnitude of heterologous responses for HIV-1 compared to HIV-2 prompted us to examine associations with viremia, which is known to be significantly higher in HIV-1 infection. Importantly, there was a significant positive correlation between the IC(50) titer and viral load within both the HIV-1 and HIV-2 groups, suggesting heterologous antibodies may be driven by viral replication. We conclude that HIV-2 infection is characterized by a broad, low-magnitude intratype neutralization response, while HIV-1 is characterized by a narrower but higher-magnitude intratype response and that a significant positive association between the IC(50) titer and viremia is common to both HIV-1 and HIV-2 infections.

Indexed as

AdultCross ReactionsDisease ProgressionFemaleHIV-1HIV-2HIV AntibodiesHIV InfectionsHumansNeutralization TestsSenegalViral LoadViremiaHIV Antibodies

Identifiers

PMID17301136
PMCPMC1900200
OpenAlexW2120621204

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.